Skip to Content

UCB SA ADR UCBJY

Morningstar Rating
$40.52 +1.66 (4.27%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

UCBJY is trading at a 19% discount.
Price
$40.69
Fair Value
$14.47
Uncertainty
High
1-Star Price
$56.23
5-Star Price
$78.51
Economic Moat
Gbs
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if UCBJY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$38.86
Day Range
$40.1940.54
52-Week Range
$34.8548.45
Bid/Ask
$39.05 / $42.44
Market Cap
$15.37 Bil
Volume/Avg
19,000 / 16,768

Key Statistics

Price/Earnings (Normalized)
18.74
Price/Sales
2.91
Dividend Yield
1.81%
Dividend Yield (Forward)
1.81%
Total Yield
2.38%

Company Profile

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Core
Total Number of Employees
8,703

Competitors

Valuation

Metric
UCBJY
JAZZ
GMAB
Price/Earnings (Normalized)
18.749.1823.60
Price/Book Value
1.562.194.61
Price/Sales
2.912.238.50
Price/Cash Flow
14.396.8722.70
Price/Earnings
UCBJY
JAZZ
GMAB

Financial Strength

Metric
UCBJY
JAZZ
GMAB
Quick Ratio
0.771.4111.36
Current Ratio
1.132.0611.38
Interest Coverage
5.840.65177.50
Quick Ratio
UCBJY
JAZZ
GMAB

Profitability

Metric
UCBJY
JAZZ
GMAB
Return on Assets (Normalized)
4.60%9.37%17.79%
Return on Equity (Normalized)
8.10%31.71%19.98%
Return on Invested Capital (Normalized)
6.68%14.19%17.39%
Return on Assets
UCBJY
JAZZ
GMAB

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRJyfy$454.3 Bil
VRTX
Vertex Pharmaceuticals IncBhzgwp$90.3 Bil
REGN
Regeneron Pharmaceuticals IncKljvf$89.7 Bil
SGEN
Seagen Inc Ordinary SharesRypbg$40.2 Bil
MRNA
Moderna IncCrsy$30.5 Bil
ARGX
argenx SE ADRLfhs$27.0 Bil
BNTX
BioNTech SE ADRBwp$23.8 Bil
ALNY
Alnylam Pharmaceuticals IncYhsrzm$21.7 Bil
BMRN
Biomarin Pharmaceutical IncNrngxcv$17.8 Bil
INCY
Incyte CorpYrptbnw$12.3 Bil